41% Risk of Death Reduction: SELLAS May Have a Major New AML Treatment on Its Hands

CryptoWire
Today at 2:04pm UTC

By Ben Hansel, Senior Financial Editor 247MarketNews

DENVER, Colo. (247MarketNews) — SELLAS Life Sciences Group (NASDAQ:SLS) has reported a potentially transformative clinical milestone, announcing that its pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) met its primary endpoint, demonstrating a statistically significant overall survival benefit in patients with certain high-risk forms of acute myeloid leukemia (AML).

The results are significant because the study evaluated patients who had reached a second or later remission but were unable to undergo an allogeneic stem cell transplant. This is a particularly challenging population with limited treatment options and a substantial risk of relapse.

According to SELLAS, patients receiving GPS achieved median overall survival of 24.0 months, compared with 14.7 months for patients receiving investigator-selected best available treatment. The reported hazard ratio was 0.59, representing a 41% reduction in the relative risk of death. The result achieved a two-sided p-value of 0.035, meeting the trial’s prespecified statistical threshold.

Importantly, this was not an early-stage signal or an exploratory analysis. REGAL was a randomized, open-label, Phase 3 registrational study involving 126 patients, with its primary analysis conducted after the prespecified 80 death events had occurred. That makes the announcement a major development for a company whose investment thesis has been heavily tied to GPS reaching this milestone.

GPS is an investigational immunotherapeutic cancer vaccine designed to train the immune system to recognize and attack cancer cells expressing WT1, a protein found in several hematologic malignancies and solid tumors. Unlike conventional chemotherapy, the approach is intended to target residual leukemia cells through an immune response.

SELLAS reported that GPS was generally well tolerated, with predominantly mild-to-moderate treatment-related adverse events and no new safety signals. That could become an important consideration in a maintenance-treatment setting, where patients may need therapy over an extended period.

SELLAS says it plans to meet with the FDA to discuss an accelerated filing strategy and is preparing for a potential Biologics License Application (BLA) submission in the first half of 2027.

That creates a relatively defined sequence of upcoming milestones: regulatory discussions, release of comprehensive trial data at a major medical conference, peer-reviewed publication, and potentially a BLA filing.

For SELLAS, the REGAL announcement changes the company’s position considerably. GPS has moved beyond the uncertainty of whether its pivotal study could demonstrate an overall survival benefit. The next challenge is translating that result into a regulatory submission and, ultimately, an approved treatment.

The company also has another clinical asset, SLS009, a CDK9 inhibitor being developed for AML and other hematologic malignancies. That provides a separate development program, although GPS is now clearly the immediate focus following the REGAL results.

About the Author

Ben Hansel is a financial and business writer with a background in business, sales, and finance. He graduated from the University of Texas at El Paso. His professional and educational background informs his coverage of financial markets, corporate developments, economic trends and the broader forces shaping the market.

Important Editorial Note: 247MarketNews highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication.  Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.